Metal and Lipid Nanoparticle Manufacturing Market

Majority of big pharma players that offer a wide range off the shelf products and custom services associated with nanoparticles are headquartered in the US. Further, given the rising interest of developer companies to avail contract manufacturing services, such service providers are likely to witness lucrative market opportunities in the foreseen future

-CEO, Europe based Small Sized Company

Metal and Lipid Nanoparticle Manufacturing Market Overview

The metal and lipid nanoparticle manufacturing market (service) is estimated to be worth $2.1 billion in 2021 and is expected to grow at compounded annual growth rate (CAGR) of 8.6% during the forecast period. Over the past few decades, the pharmaceutical industry has witnessed significant growth, as also evident from the continuously growing pipeline of drug candidates that have been marketed or are being evaluated across several development stages. However, a recent study published in the journal of Analytical and Pharmaceutical Research has highlighted that around 90% of the candidates in the current preclinical development pipeline and more than 40% of the marketed pharmacological products are associated with concerns related to solubility / permeability. Further, it was observed that a pharmacological product became 10% less vigorous, each time, when mixed with another product, due to drug incompatibility.Therefore, players engaged in metal and lipid nanoparticle manufacturing market are actively trying to identify ways to improve / augment physiochemical properties and drug-like behavior of pharmacological products. Amidst other alternatives, the use of nanoparticles has garnered the attention of many drug developers. In fact, the novel vaccines developed to treat COVID-19 are enclosed within a layer of lipid nanoparticles; these molecules assist the delivery of active ingredients to the required site of action. Moreover, many drug developers are using lipid / metal nanoparticles to re-formulate existing product candidates in order to further improve their bioavailability / biocompatibility. However, for some of the nanoparticles having medical applications, the associated manufacturing processes are highly complex, capital-intensive and fraught with multiple challenges, such as need for specialized expertise (especially in case of lipid nanoparticles), lack of facilities with necessary infrastructure, as well as concerns related to storage and stability. Considering the routine operations-related and technical challenges, an increased number of pharmaceutical companies have demonstrated the preferences to outsource their respective nanoparticle production operations to specialized service providers. 

There are numerous benefits of engaging contract development and manufacturing (CDMO) / biologics contract manufacturing organizations (CMO) for nanoparticle manufacturing; for instance, contracting a supplier for medical grade nanoparticles enables sponsors to leverage new technologies (available with the service provider), access larger capacities and achieve greater operational flexibility. Presently, there are several contract manufacturers and technology providers, who claim to have the required capabilities to manufacture nanoparticles (lipid and metal nanoparticles). However, the global expertise and capabilities necessary for the production of GMP grade nanoparticles are currently limited. As a result, many companies offering contract manufacturing services for nanoparticles are actively trying to consolidate their presence in metal and lipid nanoparticle manufacturing market, by entering into various strategic alliances to broaden their respective service portfolios. It is also worth highlight that, recently, a number of deals were inked between vaccine developers and CMOs in order to cater the urgent need for nanoparticle-based solutions for the development of COVID-19 vaccines. Given the benefits of using nanoparticles to improve drug-like properties, we believe, that the demand for high quality nanoparticles is likely to drive considerable market growth within the specialty contract manufacturing market in the forecast period.

Key Companies Offering Services in Metal and Lipid Nanoparticle Manufacturing Market

Examples of key companies engaged in providing services in metal and lipid nanoparticle manufacturing market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Ardena, CordenPharma, Curia, Evonik, LSNE Contract Manufacturing, Polymun and TechNanoIndia. This market report includes an easily searchable excel database of all the companies providing nanoparticles contract manufacturing, worldwide.

Recent Developments in Metal and Lipid Nanoparticle Manufacturing Market:

Several recent developments have taken place in the field of metal and lipid nanoparticle manufacturing market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

• In April 2026, Genflow Biosciences announced a strategic technology collaboration to advance LNP-based delivery systems integrated with SIRT6 mRNA payloads for gene therapy programs, leveraging nanoparticle manufacturing expertise in Europe to accelerate clinical development timelines.
• In April 2026, Ardena acquired a US manufacturing plant to enhance capacity amid geopolitical supply chain challenges, strengthening its position in contract manufacturing for complex nanoparticle drug products.
• In February 2026, Cellipont Bioservices entered into a collaboration with Soter Bio providing integrated RNA/LNP and cell therapy manufacturing services, enabling end-to-end production for advanced therapeutics in the US with scalable nanoparticle capabilities.

Scope of the Report

The “Metal and Lipid Nanoparticle Manufacturing Market by Company Size (Very Small Companies, Small Companies, Mid-Sized Companies, and Large Companies), Type of Nanoparticle(s) Manufactured (Lipid and Metal Nanoparticles), Scale of Operation (Preclinical, Clinical, and Commercial), Type of End User (Educational Institutions, Pharmaceutical Companies, Research Institutions, and Other End Users), and Key Geographical Regions (North America, Europe, Asia, Middle East and North Africa (MENA),  Latin America, and Rest of the World): Industry Trends and Global Forecasts, 2021-2035” market report features an extensive study of the current market landscape, market size, market forecast and future opportunities for the contract service providers engaged in manufacturing of nanoparticles for the purpose of preclinical development, clinical research and commercialization. The market research report features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in metal and lipid nanoparticle manufacturing market.

Amongst other elements, the market report features:

• A detailed overview  of the current market landscape of nanoparticle contract manufacturers, along with information on several relevant parameters, such as year of establishment, company size (very small, small, mid-sized and large), location of headquarters, type of organization (CDMO and CMO), type of nanoparticle(s) manufactured (lipid and metal nanoparticles), location and number of manufacturing facilities, scale of operation (preclinical, clinical, and commercial), type of end user (educational institutions, pharmaceutical companies. research institutions, and other end users), type of service(s) offered, quality certifications and regulatory organizations. 
• An in-depth analysis, highlighting  the contemporary market trends using six schematic representations, including [A] a bubble representation based on company size and type of organization, [B] a comparative world map representation, based on company size, location of the headquarters and type of nanoparticle(s) manufactured, [C] a stacked bar chart representation based on company size and scale of operation, [D] a heat map representation highlighting the regional distribution of developers engaged in metal and lipid nanoparticle manufacturing market,  [E] a 4D bubble analysis comparing the leading players engaged in metal and lipid nanoparticle manufacturing market, based on several relevant parameters (such as company size, type of nanoparticle(s) manufactured, number of manufacturing facilities, and number of service(s) offered), [F] a grid representation illustrating the distribution of nanoparticle contract manufacturers based several relevant parameters (such as type of organization, type of nanoparticle(s) manufactured, scale of operation, type of end user, and type of service(s) offered).
• An in-depth company competitiveness analysis of nanoparticle contract manufacturers, based on several relevant parameters, such as company’s service strength (taking into consideration years of experience, type of organization, type of nanoparticle(s) manufactured, number of manufacturing facilities, scale of operation, type of end user and type of service(s) offered) and partnership strength (taking into consideration the number of partnerships and type of agreement).
• Elaborate profiles of key players that offer contract manufacturing services for nanoparticle(s). Each profile features a brief overview of the company, along with information on year of establishment, location of headquarters, number of employees, key executives, recent developments and an informed future outlook.
• An analysis of recent partnerships inked between various stakeholders engaged in metal and lipid nanoparticle manufacturing market, during the period 2015-2021, based on several relevant parameters, such as year of partnership, type of partnership (company acquisitions, manufacturing agreements, mergers, product development agreements, product distribution agreements, technology integration agreements, and other agreements), type of partner, type of nanoparticle(s) manufactured, emerging focus area, seniority level of stakeholders, most active players (in terms of number of partnerships), type of agreement and regional distribution.
• An insightful analysis, highlighting the various factors that need to be taken into consideration by nanoparticle(s) developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO. Further, the analysis highlights all the key parameters that must be considered by players based on company sizes (very small, small, mid-sized, and large), while taking the aforementioned decision.

One of the key objectives of this market report is to provide a detailed market forecast analysis in order to estimate the existing market size and future opportunity of the nanoparticle contract manufacturing market during the forecast period. We have also provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, over the forecast period 2021-2035. Additionally, the market report features the likely distribution of the current and forecasted opportunity across [A] company size (very small, small mid-sized, and large), [B] type of nanoparticle(s) manufactured (lipid and metal nanoparticles), [C] scale of operation (preclinical, clinical and commercial) and [D] type of end user (educational institutions, pharmaceutical companies, research institutions, and other end users), and [E] key geographical regions (North America, Europe, Asia, MENA, Latin America and rest of the world).  In order to account for future uncertainties in the market and add robustness to our forecast model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the market’s evolution. The opinions and insights presented in the market report were also influenced by discussions held with senior stakeholders in the industry. 

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.